Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Dendreon Expands Launch of PROVENGE

March 10, 2011 By Bio-Medicine.Org

SEATTLE, March 10, 2011 /PRNewswire/ — Dendreon Corporation
(Nasdaq:
DNDN) announced today that the U.S. Food and Drug
Administration (FDA) approved the remainder of its New Jersey
manufacturing facility, allowing the company to significantly
increase the availability of PROVENGE® (sipuleucel-T) to help
meet the needs of patients with asymptomatic or minimally
symptomatic metastatic castrate resistant (hormone refractory)
prostate cancer.  

Last April, upon receiving FDA approval of PROVENGE, Dendreon
launched the world’s first patient-specific prostate cancer
immunotherapy from 12 workstations in its New Jersey facility.
 With the FDA approval of 36 additional workstations, the New
Jersey facility will now have a total of 48 approved workstations.
 Dendreon will bring these new workstations online in a staged
approach.  

PROVENGE is designed to induce an immune response against
prostatic acid phosphatase (PAP), an antigen expressed in most
prostate cancers, and is the first in a new therapeutic class of
drugs known as autologous cellular immunotherapies.

“PROVENGE has the largest reported survival benefit in patients
with asymptomatic or minimally symptomatic metastatic prostate
cancer, with the most common side effects being primarily transient
and mild to moderate. As such, PROVENGE is the standard of care for
these patients,” said Daniel George, M.D., director of GU Medical
Oncology and the Prostate Clinic at Duke University Medical Center.
“The increased availability of PROVENGE will allow more treatment
centers and patients across the country to access this important
treatment option.”

In anticipation of the availability of the additional
workstations, Dendreon expects to have approximately 225 infusion
centers prepared to treat their first patient by the end of the
second quarter, approximately 450 infusion centers upon en

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech